Cardiac Calcium Channel Blocker Therapy represents a fundamental aspect of cardiovascular care, offering a targeted approach to managing heart-related conditions. These blockers, recognized as calcium antagonists, exert their therapeutic effects by impeding the entry of calcium ions into cardiac muscle cells. This mechanism proves particularly valuable in addressing diverse cardiovascular issues, ranging from hypertension and angina to specific arrhythmias. By facilitating the dilation of blood vessels and promoting cardiac relaxation, calcium channel blockers contribute to improved blood flow and reduced strain on the heart. The incorporation of these medications into a comprehensive treatment strategy underscores their role in optimizing cardiovascular health. It remains imperative for healthcare professionals to personalize prescriptions based on individual patient profiles, ensuring that the therapeutic benefits are maximized while mitigating potential side effects. The dynamic landscape of Cardiac Calcium Channel Blocker Therapy remains a driving force in advancing cardiovascular medicine and elevating the standard of care for individuals with heart-related conditions.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation